Cutting-Edge Cancer Vaccines Enhanced by Nanotechnology
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".
Deadline for manuscript submissions: 30 April 2025 | Viewed by 123
Special Issue Editor
Interests: cancer immunotherapy; nanotechnology; cancer vaccine; adjuvant; in situ cancer vaccine; cancer combination therapy; nanoparticle; immune checkpoint inhibitor
Special Issue Information
Dear Colleagues,
Cancer immunotherapies have significantly extended the survival time of cancer patients, revolutionized cancer treatment and opened a new era of cancer treatment. In cancer immunotherapy, cancer vaccines are among the most promising strategies, owing to their ability to educate the body’s immune system to recognize, target and remove tumor cells. Recently, the successful development of COVID-19 mRNA vaccines and dramatic advances in nanotechnologies have led to significant progress in developing cancer vaccines. In particular, nanotechnology can protect the delivery of antigens, enable sustained and efficient antigen delivery to specific targets, enhance immunogenicity and induce specific immune responses. Therefore, nanotechnology has played an indispensable role in the success of various clinical and preclinical vaccines.
In this Special Issue, original research articles and reviews related to the recent advances, current challenges and future perspectives in cutting-edge nanotechnology-based cancer vaccines are welcome. Research areas may include the following:
- Nanoscale synthesis, structural regulation and functional design of polymers, lipids, inorganic particles and bio-derived materials for cancer vaccines;
- Nano-vaccine adjuvants for therapeutic, prophylactic and in situ cancer vaccines;
- Nanotechnology-based cancer vaccines combined with other cancer therapies, such as immune checkpoint inhibitors;
- Mechanisms, safety and efficacy of nanotechnology-enhanced cancer vaccines.
I look forward to receiving your contributions.
Dr. Xiupeng Wang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer immunotherapy
- nanotechnology
- cancer vaccine
- adjuvant
- in situ cancer vaccine
- personalized cancer vaccine
- combination cancer therapy
- nanoparticle
